Replies to post #54907 on Biotech Values

[Kadaicher1]

What does this mean for PP
Science News Share Blog Cite Print Email BookmarkIntake Of Dietary Copper Helps Alzheimer's Patients
ScienceDaily (Oct. 4, 2005) —

As one of the services for patients with Alzheimer's disease, the Department of Psychiatry at the Saarland University Medical Center offers participation in a clinical phase II trial. This clinical trial aims to elucidate a potential beneficial effect of copper orotate (an organic copper salt), which is given together with a standard cholinesterase inhibitor. A diagnosis of mild to moderate dementia of the Alzheimer type is a prerequisite. Besides clinical investigations, laboratory investigations of blood and cerebrospinal fluid, and magnet resonance imaging of the brain will be carried out. The study is being conducted by Professor Dr. Thomas Bayer, the Head of the Division of Neurobiology, and Dr. Frank Pajonk, a Psychiatrist, at the Department of Psychiatry, Saarland University Medical Center.


--------------------------------------------------------------------------------
See also:
Health & Medicine
Alzheimer's Research
Today's Healthcare
Vitamin
Mind & Brain
Dementia
Alzheimer's
Stroke
Reference
Clinical trial
Double blind
Dementia with Lewy bodies
Dementia
Treatment starts after all prerequisites to participate have been met. Half of the patients receive 8 mg copper orotate per day, the other half a placebo. Both patients and psychiatrists are blinded. During the 12-month long double-blind phase, there will be extensive laboratory, clinical and neuropsychological tests. After the double-blind phase, we offer an open-label phase for all patients. At present, 15 patients have finished the double-blind phase. The copper medication is well tolerated.

Alzheimer is characterized by the presence of amyloid plaques, which are composed primarily of Aß peptide. Aß is produced within neurons and is liberated from the larger amyloid ß protein precursor (AßPP). Lower levels of copper have been reported in the brain of AßPP transgenic mice and post-mortem in AD patients. This concept has been found to be true also in vitro by Professor Dr. Gerd Multhaup (FU Berlin) in 1999. Two recent papers, which have been published in PNAS in 2003 have proven a beneficial effect of elevated copper in transgenic AßPP mice. In the present study, the teams led by Bayer and Multhaup have found that low copper level in blood correlates with advanced memory deficits, as tested by the well established ADAS-cog neuropsychological test battery. Patients with higher blood copper levels make fewer mistakes in this memory test. This result supports the notion of a mild copper deficiency in AD patients. An increased uptake of dietary copper may therefore be therapeutically relevant.

###

The study has been published in the September 2005 issue of the Journal of Alzheimer's Disease, Volume 8, Issue 1 published by IOS Press: "Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate Alzheimer's disease" (JAD, Vol. 8, Issue 1).

[drbio45]

After the longwinded, runaround answer by PP’s CEO to your question on Thursday’s CC, I find it astonishing that you would want to be long.

Then again, you thought HEB was a good company, so perhaps I shouldn’t be surprised you like PP.

Steven Kanzer has been buying stock on the open market. They did a warrant call to bring in cash from their warrants, so they didn't have to dilute the stock by doing a financing.

You are correct that I liked HEB many years ago. It was a mistake. Aren't we supposed to learn from our mistakes. I believe I was the first person on this board to warn people of Steven Quay, when you were getting enamored to the story. I have never made fun of, or threw sand in your eyes for mistakes that you have made. Why do you get jollys over the mistakes of others. I don't appreciate the crack above.

[DewDiligence]

More junk science from PP?
You be the judge:

http://biz.yahoo.com/iw/080528/0401329.html

[DewDiligence]

Adeona – A scam by a new name is still a scam…

http://biz.yahoo.com/pz/081016/152257.html

›Pipex Pharmaceuticals, Inc. Completes Corporate Name Change to Adeona Pharmaceuticals and Receives New Ticker Symbol

Thursday October 16, 8:45 am ET

Stock to Trade Under New Ticker Symbol 'AEN' Starting Today

ANN ARBOR, Mich., Oct. 16, 2008 (GLOBE NEWSWIRE) -- Pipex Pharmaceuticals, Inc. (the ``Company'' or ``Pipex'') (AMEX: PP ), a pharmaceutical company developing innovative late-stage oral drug candidates for the treatment of autoimmune and central nervous system diseases, announced today that it has completed a corporate name change from Pipex Pharmaceuticals, Inc. to Adeona Pharmaceuticals, Inc.

As a result of the name change, the American Stock Exchange (AMEX) will begin to trade the Company's shares of common stock as of today, under the new ticker symbol 'AEN.'

Nicholas Stergis, Chief Executive Officer of Adeona, commented, ``As previously announced, we are pleased to have completed our corporate name and ticker symbol change. Our primary focus is toward the continued development of new disease-modifying treatments for autoimmune and central nervous system diseases. This strategy and direction is evident by our recent in-licensing of oral dnaJP1 for the treatment of rheumatoid arthritis (RA) which has completed a 160-patient, double-blind, placebo-controlled phase II clinical trial in RA patients. Oral dnaJP1 complements our existing immunology pipeline which includes, TRIMESTA, an oral treatment for multiple sclerosis (MS) which is currently in a 150-patient double-blind, placebo-controlled phase IIb clinical trial is being funded by a $5 million grant.''

About Adeona

Adeona Pharmaceuticals, Inc. (``Adeona'') is a specialty pharmaceutical company that is developing proprietary, late-stage drug candidates for the treatment of central nervous system and autoimmune diseases. Adeona's strategy is to exclusively in-license clinical-stage drug candidates for the treatment of unmet medical diseases. Adeona is focused on developing products to treat, rheumatoid arthritis, multiple sclerosis, dry age-related macular degeneration (AMD), and fibromyalgia.‹

[DewDiligence]

The scam continues at AEN (formerly Pipex). Steve Kanzer, Chairman and ex-CEO of the company, is playing some new games with the AEN shares owned by Accredited Venture Capital, LLC, which is Kanzer’s own investment company.

http://sec.gov/Archives/edgar/data/894158/000113207209000021/s22-8696_ex101.htm

I continue to be astonished that David Miller recommended this stock to his newsletter subscribers in 2007-2008, and a number of regular posters on this board argued in favor of investing. The shares are down 96% since Dec 2007.